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§ ILRI has a rich history of animal health biotech 
research, including molecular diagnostics
§ ILRI has invested in different levels of bio-secure 
facilities, including a high-containment BSL-3 lab
§ The generic nature of ILRI’s modern bioscience 
facilities and expertise allowed us to rapidly re-
purpose for COVID-19 testing under safe and secure 
conditions
§ Over 10,000 samples have been tested for presence 
of SARS-CoV-2 viral RNA so far
§ ILRI’s investment in COVID-19 testing reflects its full 
commitment to demonstrating how the One Health 
approach translates to practice
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Context
• The COVID-19 pandemic has had a negative impact on 
human life and the global economy.
• Timely diagnostic tests to identify infected individuals play 
a major role in controlling spread of the SARS-CoV-2 virus.
• At the onset of increased virus transmission in Kenya, the 
Kenyan Ministry of Health requested ILRI to support its 
national COVID-19 diagnostic effort.
• Leveraging our molecular diagnosis and infectious disease 
research experience and expertise, part of our facilities 
were repurposed for COVID-19 testing. 
• Supported by the Ministry for Economic Cooperation and 
Federal Development (BMZ) under the ILRI-led One Health 
Research, Education and Outreach Centre for Africa 
(OHRECA), and the Government of Kenya, COVID-19 
testing was launched on 1st June 2020. 
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Results/Impact
• Several diagnostic kits, sample work-flows and process 
were optimized and validated prior to starting the service.
• Samples received from Kenyan government institutions & 
labs are deactivated and processed in a BSL-3 lab prior to 
PCR testing in a clean BSL-2 room. This ensures high 
safety and quality standards are maintained. 
• Results are returned to Ministry of Health within 24hrs:
o Data is used at an individual level to identify positive 
cases and guide control measures, e.g. quarantine. 
o Nationally the data helps estimate the rate of virus 
spread to set national policies for public health.
Fig.1. Graphical data outputs of PCR testing for COVID-19
Partners
Future steps 
• Develop in-house reagents to support COVID-19 testing 
and reduce costs.
• Leverage ILRI’s whole genome sequencing and genomic 
platforms to support COVID-19 research: virus 
surveillance, evolution, vaccine and drug development
• Extend the diagnostic capacity to investigate pathogens 
at the wildlife-livestock-human-environment interface 
to help prevent spill-over events.
• Help develop capacity for diagnostics and rapid 
response for surveillance.
We acknowledge with thanks the loan of a PCR machine to this 
effort by CIFOR-ICRAF (World Agroforestry) and KEMRI-Wellcome
Trust labs for sharing information and materials
Our innovative approach
6. Waste management
• Autoclave & Incinerate –solid waste
• Effluent treatment – Liquid waste








• RT-PCR reaction set-up
1. Sample reception 
• Sample quality & safety 
checks
• Metadata entry




• Aliquoting & storage
• Nasal/Oral sawbs in VTM: Liquid Nitrogen
• RNA extracts:  – 80 0C ultra low freezer
